期刊文献+

重组人血管内皮抑制素对多发性骨髓瘤内皮细胞增殖和迁移的影响

Effects of recombinant human endostatin on proliferation and migratory of vascular endothelial cells in mutiply myeloma
下载PDF
导出
摘要 目的观察重组人血管内皮抑制素注射液(内皮抑素)对人脐静脉内皮细胞株(HUVEC)和多发性骨髓瘤细胞株KM3抑制增殖及诱导凋亡的作用,研究其对KM3细胞培养上清诱导的HUVEC迁移效果的影响。方法 WST-1法观察不同浓度的内皮抑素分别对HUVEC和KM3细胞株的增殖抑制作用,Annexin V-FITC法检测有效浓度的内皮抑素对HUVEC和KM3细胞株的凋亡作用,改良的Boyden小室法检测内皮抑素对KM3细胞株培养上清诱导的HUVEC迁移的影响。结果 50~500 ng/mL内皮抑素对HUVEC具有抑制增殖作用,而对KM3细胞未见明显作用。100、200 ng/mL的内皮抑素对HUVEC具有诱导凋亡作用;而对KM3细胞未见明显作用。与不加药组相比,内皮抑素能抑制KM3细胞培养上清促内皮细胞迁移的作用(P<0.01)。结论内皮抑素能抑制HUVEC的增殖及诱导其凋亡,并能抑制骨髓瘤细胞的促内皮细胞迁移作用。 To observe the effect of inhibiting proliferation and inducing apoptosis effect of recombinant hu- man endostatin (ES) on the human umbilical vein endothelial cells (HUVECs) and myeloma cell lines KM3, and investigate its influence on HUVEC immigration induced by KM3 cell cultured supematant. Methods Cell proliferation in different concentration of ES was determined by WST-1 assay. The fluorescence flow cytometry ( FCM ) Annexin VFITC assay was applied to detect the changes of apoptotic cells. Modified Boyden chamber assay was used to observe the migration activity of HUVEC induced by KM3 cells. Results 50-500 ng/mL ES inhibited HUVEC proliferation, but had no influence on KM3 cell lines. 100, 200 ng/mL ES induced HUVEC apoptosis, but had no effect on KM3 cell lines. ES inhibited the endothelial cell migration induced by KM3 cell cultrued supematant(P 〈 0.01 ). Conclusion ES can not only inhibit the proliferation and induce apoptosis of HUVEC cells but also inhibit endothelial cell migration ability of multiple myeloma cells.
出处 《山东医药》 CAS 2012年第1期16-18,共3页 Shandong Medical Journal
基金 南通市科技局社会发展项目资助(S2009026)
关键词 多发性骨髓瘤 内皮抑素 内皮细胞 细胞运动 multiple myeloma endostar endothelial cells cell movement
  • 相关文献

参考文献10

  • 1Folkman J.Clinical applications of research on angiogenesis[J].NEngl J Med,1995,333(26):1757-1763.
  • 2Rajkumar SV,Leong T,Roche PC,et al.Prognostic value of bonemarrow angiogenesis in multiple myeloma[J].Clin Cancer Res,2000,6(8):3111-3116.
  • 3Munshi NC,Wilson C.Increased bone marrow microvessel densityin newly diagnosed multiple myeloma carries a poor prognosis[J].Semin Oncol,2001,28(6):565-569.
  • 4Ling Y,Yang Y,Lu N,et al.Endostar,a novel recombinant humanendostatin,exerts antiangiogenic effect via blocking VEGF-inducedtyrosine phosphorylation of KDR/F1k-1 of endothelial cells[J].Bioehem Biophys Res Commun,2007,361(1):79.
  • 5O’Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endoge-nous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88(2):277-285.
  • 6Folkman J.Antiangiogenesis in cancer therapy-endostatin and itsmechanisms of action[J].Experimental Cell Research,2006,312(5):594-607.
  • 7Rajkumar SV,Leong T,Roche PC,et al.Prognostic value of bonemarrow angiogenesis in multiple myeloma[J].Clin Cancer Res,2000,6(8):3111- 3116.
  • 8Munshi NC,Wilson C.Increased bone marrow microvessel densityin newly diagnosed multiple myeloma carries a poor prognosis[J].Semin Oncol,2001,28(6): 565-569.
  • 9Ling Y,Yang Y,Lu N,et al.Endostar,a novel recombinant hu-man endostatin,exerts antiangiogenic effect via blocking VEGF-in-duced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells[J].Bioehem Biophys Res Commun,2007,361(1):79.
  • 10Celik I,Surucu O,Dietz C,et al.Therapeutic efficacy of endosta-tin exhibits a biphasic dose-response curve[J].Cancer Res,2005,65(23):11044-11050.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部